Mack Forster Award Lecture. Receptor nuclear medicine: Vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumour patients

European Journal of Clinical Investigation

Volumn 27, Issue 10, 1997, Pages 793-800

  Virgolini, I ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

MAURITIUS; Octreotide; P829; Radioimaging; Radioligand; Receptor; Somatostatin; Tumour; VIP

Indexed keywords

MEMBRANE RECEPTOR; OCTREOTIDE; RADIOISOTOPE; RADIOLIGAND; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

CANCER DIAGNOSIS; DIAGNOSTIC IMAGING; HUMAN; LIVER METASTASIS; NEUROENDOCRINE TUMOR; NUCLEAR MEDICINE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY;

EID: 0030773660     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1997.1990742.x     Document Type: Review

References (51)

1. 99mTc-galactosyl-neoglycoalbumin:in vivo characterization of receptor-mediated binding to hepatocytes. Radiology 1984?;151:191-6.
2. Virgolini I, Müller C, Klepetko W et al. Decreased hepatic function in patients with hepatoma or liver metastases monitored by a hepatocyte specific galacto-sylated radioligand. Br J Cancer 1990;61:937-41.
3. 99mTc-galactosyl-neoglyco-albumin. Hepatology 1990;5:593-8.
4. Kurtaran A, Li SR, Raderer M et al. Technetium-99m-Galactosylneoglycoalbumin combined with iodine-123-Tyr-(A14)-insulin visualizes human hepatocellular carcinomas. J Nucl Med 1995;36:1875-81.
5. Virgolini I, Rauscha F, Lupattell G et al. Autologous low density lipoprotein-labeling allows characterization of human atherosclerotic lesions in vivo as to presence of foam cells and endothelial coverage. Eur J Nucl Med 1991;18:948-51.
6. 111in-labelled high density lipoprotein (HDL) to platelets of normolipemic volunteers and patients with heterozygous familial hypercholesterolemia. Arterioscler Thromb 1992;12:849-61.
7. 1 onto monocytes in patients with peripheral vascular disease. Arterioscler Thromb 1997: (in press).
8. 123I-VEGF(vascular endothelial growth factor): potential for imaging the endothelium. Eur J Nucl Med 1997;24:889(A).
9. Shih I-L, Lees RS, Chang MY, Lees AN. Focal accumulation of an apolipoprotein B-based synthetic oligopeptide in the healing rabbit arterial wall. Proc Natl Acad Sci USA 1990;87:1436-40.
10. Muto P, Lastoria S, Varrella P et al. Detecting deep venous thrombosis with technetium-99m-labelled synthetic peptide P280. J Nucl Med 1995;36:1384-91.
11. Geissler K, Öhler L, Födinger M, Virgolini I. Interleukin-10 inhibtis growth and granulocyte/macrophage-colony stimulating factor production in chronic myelomonocytic leukemia cells. J Exp Med 1996;184:1377-84.
12. Sillaber C, Baghestanian M, Virgolini I et al. Molecular and functional characterization of the urokinase receptor on human mast cells. J Biol Chem 1997;272:7824-32.
13. Raderer M, Banyai M, Kurtaran A et al. Imaging of human tumours and venous thrombosis with 1231-labelled recombinant human tissue type plasminogen activator (rH-TPA). Eur J Clin Invest 1996;26:A56
14. 123I-interferon gamma-lb. J Nucl Med 1997;38: 880-91.
15. Lamberts SWJ, Bakker WH, Breeman WA et al. Localisation of endocrine-related tumours with radioiodinated analogueue of somatostatin. Lancet 1989;1:242-4.
16. 123I-Tyr-3-octreotide:the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
17. Krenning EP, Kwekkehoom DJ, Pauwels S, Kvols K, Reuhi JC. Somatostatin receptor scintigraphy. Nucl Med Ann 1995:1-50.
18. Vallabhajosula S, Moyer B, Lister-James J et al. Preclinical evaluation of technetium-99m-labelled somatostatin receptor-binding peptides. J Nucl Med 1996;37:1016-22.
19. Lastoria S, Muto P, Acampa W et al. Somatostatin receptor scintigraphy with 99mTc-P829 in melanoma. J Nucl Med 1996;37:138P.
20. Virgolini I, Yang Q, Li SR et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumour cell membrane receptors. Cancer Res 1994;54:690-700.
21. Virgolini I, Kurtaran A, Leimer M et al. Visualizalion of a VIPoma by vasoactive intestinal peptide. Implications of the somatostatin receptor subtype 3 (submitted).
22. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumours: Implications for tumour imaging. J Nucl Med 1995:36:1846-53.
23. Virgolini I, Raderer M, Kurtaran A et al. Vasoactive intestinal peptide (VIP) receptor imaging in the localisation of intestinal adenocarcinomas and endo-crine tumours. N Engl J Med 1994;331:1116-21.
24. Virgolini I. Kurtaran A, Raderer M et al. Vasoactive intestinal peptide receptorscintigraphy. J Nucl Med 1995;36:1732-9.
25. Raderer M, Becherer A, Kurtaran A et al. Comparison of iodine123-vasoactivc intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy. J Nucl Med 1996;37:1480-7.
26. Virgolini I, Szilvasi I, Smith-Jones P. et al. 'MAURITIUS': animal and human biodistribution and tumor localization. Eur J Nucl Med 1997;24:874(A).
27. Virgolini I, Kurtaran A, Szilvaszi I et al. 'MAURITIUS':Biodistribution, safety and tumour dose in patients evaluated for somatostatin receptor radiotherapy (submitted).
28. Said SI, Mutt V. Polypeptide with broad biological activity-Isolation fromsmall intestine. Science 1970;169:1217-18.
29. Verner JV, Morrison AB. Islet cell tumour and a syndrome of refractory watery diarrhea and hypokalemia, Am J Med 1958;25: 374-80.
30. Pincus DW, DiCicco-Bloom EM, Black IB. Vasoactive intestinal polypeptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature 1990;343:564-7.
31. Battari A, Martin JM, Luis J, Pouzol O, Secchi J, Marvaldi J, Pichon J. Solubilization of the vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells. J Biol Chem 1988;263: 17685-9.
32. Gespach C, Bawab W, de Cremoux P, Calvo F. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancers. Cancer Res 1988;48: 5079-83.
33. Brazeau P, Vale W, Burgus R et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;119:77-79.
34. Plewe G, Beyer J. Krause U, Neufeld M. Pozo del E. Long-acting and selective suppression of growth hormone secretion by somatostatin analogueue SMS 201-995 in acromegaly. Lancet 1984;6: 782-4.
35. Reichlin S. Somatostatin. N Engl J Med 1983;309:1556-3.
36. Adrian TE, Barness A, Long RG et al. The effect of somatostatin analogues on secretion and of growth, on panreatic and gastrointestinal hormones in man. J Clin Endocrinol Metab 1981;53:675-81.
37. Yamada Y, Post SR, Wang K et al. Cloning of somatostatin receptors SSTR1 and SSTR2 form the gastrointestinal tract and kidney. Proc Natl Acad Sci USA 1992;89:251-5.
38. Yamada Y, Reisine T, Law SF et al. Somatostalin receptors, an expanding gene lamily:cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocinol 1992;6:2136-42.
39. Yamada Y, Kagimoto S, Yasuda K et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and fifth (hSSTR5) human somalostatin receptor subtype. Biochem Biophys Res Commun 1993;195:844-52.
40. Yasuda K, Res-Domiano S, Breder CA et al. Cloning of a novel somatostatin receptor, SST3. coupled to adenylate cyclase. J Biol Chem 1992;267:20422-8.
41. Demchyschyn LL, Srikant CB, Sunahara RK et al. Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20. Mol. Pharmacol 1993;43:894-901.
42. Bell GI, Yasada K, Kong H et al. Molecular biology of somatostatin receptors. Ciba Foundation Symposium 1995;190:65-88.
43. Corness JD, Demchyshyn LL, Seeman P, A human somalostatin receptor (SSTR3). located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS 1993;321:279-284.
44. Rohrer L, Raulf F. Bruns C et al. Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci USA 1994;90:4196-200.
45. -1 receptor present in human SUP-T1 lymphoma cell membranes. Regul Pept 1989;26: 117-26.
46. Ishihara T, Shigemoto R, Mori K, Takahashi Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 1992;8:811-19.
47. Lutz EM, Sheward WJ, West KM, Fink G, Harmar AJ. The VIP2 receptormolecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 1994;334: 3-8.
48. Svoboda M, Tastenoy M, Rampelbergh J van et al. Molecular cloning and functional characterization of a human VIP receptor from sup-T1 lymphoblasts. Biochem Biophys Res Commun 1994;205:1617-24.
49. Usdin TB, Bonner TI, Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 1994;135:2662-80.
50. Couvineau A, Rouyer-Fessard C, Darmoul D et al. Human intestinal VIP receptor:cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem Biophys Res Commun 1994;200:769-76.
51. Krenning KE, Kwekkeboom D, DeJong M et al. Somatostatin receptor:scintigraphy and radionuclide therapy. Digestion 1996; 57:57-61.